Reporting to the General Counsel, the Vice President, Corporate, Securities & Transactions will work closely with the General Counsel on Allogene’s public company corporate legal function, including SEC reporting, corporate governance, Board and committee matters, proxy and annual meeting processes, Section 16 reporting, and related disclosure and compliance matters. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.